JAC Advance Access published online on September 6, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl375
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medical HIV Treatment & Research Unit, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
* To whom correspondence should be addressed. Objectives: To evaluate the virological, immunological and clinical responses to the boosted double protease inhibitor (PI) regimen combination of lopinavir/ritonavir and saquinavir (‘LOPSAQ’) without reverse transcriptase inhibitors (RTI) in HIV-positive patients who have few viable RTI treatment options. Methods: Cohort study of 128 heavily pre-treated patients who were experiencing therapy failure on their current regimen due to RTI resistance and/or systemic toxicities. Patients with PI-resistance mutations or RTI toxicity underwent a structured treatment interruption (STI) (n = 76) until virus reverted to wild-type or until resolution of toxicity symptoms. Baseline was defined as the time point when lopinavir/ritonavir plus saquinavir therapy was initiated. Virological response was defined as viral load <400 copies/mL at week 48. Results: A total of 78 (61%) patients experienced a virological response to therapy (ITT). Median viral load at baseline was 5.06 log10 copies/mL; at week 48 median was 2.16 log10 copies. Median CD4 at week 48 was 280 cells/mm3 compared with 172 cells at baseline. At week 48, 78/128 patients were still on therapy. In univariable analyses, significant predictors of virological response included higher CD4 count (P < 0.001), lower viral load (P = 0.002), less PI-experience (P = 0.006) at baseline and fewer PI-resistance mutations (P = 0.043) at end of prior failing regimen; in the multivariable analysis only higher CD4 count at baseline (P = 0.009) and fewer number of drugs previously taken (P = 0.003) could be specified as independent predictors for response. Conclusions: The combination of lopinavir/ritonavir and saquinavir without RTIs is a potential option as salvage therapy for patients experiencing therapy failure due to RTI resistance or toxicity. This regimen may not be suitable for patients with very low baseline CD4 cell counts, very broad antiretroviral therapy experience or extensive PI-resistance mutations.
Received June 27, 2006
Revised August 17, 2006
Accepted August 20, 2006
Original article
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy
Schlomo Staszewski 1, Errol Babacan 1, Christoph Stephan 1, Annette Haberl 1, Amina Carlebach 1, Peter Gute 2, Stephan Klauke 3, Yvonne Hermschulte 4, Martin Stuermer 4, and Brenda Dauer 1 *, for the Frankfurt HIV Cohort
2 Private HIV Practice Gute/Locher/Lutz, Frankfurt, Germany
3 Internistisches Facharztzentrum Stresemannallee, Frankfurt, Germany
4 Department of Virology, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
Brenda Dauer, E-mail: brenda.dauer{at}hivcenter.de
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Stebbing, A. Scourfield, G. Koh, C. Taylor, S. Taylor, E. Wilkins, B. Gazzard, M. Nelson, and R. Jones A multicentre cohort experience with double-boosted protease inhibitors J. Antimicrob. Chemother., August 1, 2009; 64(2): 434 - 435. [Full Text] [PDF]
|
|
|
|
|
|
R. Landman, C. Capitant, D. Descamps, C. Chazallon, G. Peytavin, C. Katlama, G. Pialoux, M. Bentata, F. Brun-Vezinet, J.-P. Aboulker, et al. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study J. Antimicrob. Chemother., July 1, 2009; 64(1): 118 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Robbins, E. V. Capparelli, E. G. Chadwick, R. Yogev, L. Serchuck, C. Worrell, M. E. Smith, C. Alvero, T. Fenton, B. Heckman, et al. Pharmacokinetics of High-Dose Lopinavir-Ritonavir with and without Saquinavir or Nonnucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3276 - 3283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Hentig, P. Kaykhin, C. Stephan, E. Babacan, M. Sturmer, S. Staszewski, and J. Lotsch Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2273 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. van der Lugt, R. S. Autar, S. Ubolyam, E. F. Garcia, J. Sankote, A. Avihingson, T. Chuenyam, D. A. Cooper, J. Lange, P. Phanuphak, et al. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults J. Antimicrob. Chemother., May 1, 2008; 61(5): 1145 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Hentig, A. Muller, C. Rottmann, T. Wolf, T. Lutz, S. Klauke, M. Kurowski, B. Oertel, B. Dauer, S. Harder, et al. Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1431 - 1439. [Abstract] [Full Text] [PDF]
|
|